Qubit Pharmaceuticals

Qubit Pharmaceuticals develops ATLAS, a platform for high-precision molecular simulation, modeling and molecule generation that combines quantum physics, AI and computational chemistry. The company states that ATLAS reduces the time needed to select and optimize a drug candidate by half. It also runs its own drug discovery programs, with a stated focus on oncology, inflammation and pandemic response.

The company describes its customers and partners as pharmaceutical and biotech organisations. It states that it seeks joint drug discovery partnerships and in-licensing opportunities in inflammation and oncology. The website lists fully owned and partnered programs in discovery.

The company says it was founded in 2021, and it is headquartered in Paris with an office in Boston; the website also names Chicago among its offices. The website reports over 60 employees and a team with more than 18 nationalities. One open role is listed: Head of Quantum Computing in Paris. Its founders include academics from Sorbonne Université, Cnam, Washington University in St. Louis and the University of Texas at Austin.

Product: ATLAS, a quantum, AI and physics-inspired platform for high-precision molecular simulation, modeling and molecule generation.